About US
Contact us
-
Medivation has 'best-in-class' ambitions for newly purchased PARP inhibitorMedivation ($MDVN) made a name for itself withXtandi, the prostate cancer med that's now giving Johnson & Johnson's ($JNJ) Zytiga a run for its money. Now, it wants to challenge other drugmakers i2015/8/27
-
UPDATED: Novo to spend $1.2B, hire 700 for its first major drug plant in U.S.With a game-changing oral diabetes treatment moving through clinical trials, Novo Nordisk ($NVO) will spend about $1.2 billion on its firstAPIplant in the U.S., a project that is expected to bring 7002015/8/27
-
Stock slide makes biopharma deals more enticing for Gilead (and everyone else)Analysts and investors may have been ready for Gilead Sciences ($GILD) to make an M&A move before now. But with stocks on a slide, they might be glad Gilead hasn't yet. As theWall Street Journalp2015/8/26
-
Teva bows out of voting on Mylan's proposed deal for PerrigoFriday, Mylan's ($MYL) shareholders will vote on whether the company should move ahead with its hostile bid for Perrigo ($PRGO). But Teva ($TEVA) won't be among them, despite the fact that it built up2015/8/26
-
J&J uses share-the-wisdom approach to spread the word on PrezcobixJohnson & Johnson ($JNJ) is trying a new tack on the old "talk to your doctor" advice. With a new campaign for its HIV drug Prezcobix, the company is urging potential patients to snap a photo and2015/8/25
-
Allergan recalls eye drugs after patients complain of particles, blurred visionSince Allergan ($AGN) andActavisjoined hands to become a new-look Allergan, the company has already had to recall a product from the Actavis side. Now, it's recalling some from the Allergan side, putt2015/8/25
-
Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects of China's stock market m2015/8/24
-
Ackman's Valeant ties pay off yet again with Sprout buyBill Ackman's relationship with Valeant has paid off big-time since the hedge fund manager first teamed up with the Canadian pharma on its hostile pursuit of Allergan ($AGN). And this time, it's an in2015/8/24
-
Approval system reform for drugs, medical instrumentsChina has decided to reform its appraisal and approval system for drugs and medical instruments with the aim of improving drug safety and quality and encouraging innovation. According to a guideline2015/8/21
-
GSK OTC push marred by super-sized recall of toothpasteThe decision of GlaxoSmithKline ($GSK) CEOAndrew Wittyto double down on consumer health products has not been very popular with some investors, who question the strategy of focusing on low-margin, hig2015/8/21